CLINICAL ROLE -
Brain Cancer Combination Extends Progression Free Survival, Not Overall Survival
Treatment with bevacizumab and lomustine not found to offer a survival advantage.
Read More
Early Chemotherapy Less Likely to Benefit African American Women
Chemosensitivity, treatment variations, and socioeconomic factors may be a significant factor.
Severe Hemophilia Antibody May Enhance Current Treatment
Engineered antibody treatment imitates functioning factor VIII to make blood clot properly.
New Biosimilar Under Review in Top Specialty Pharmacy News
Catch up with any news you missed this week on Specialty Pharmacy Times.
Application for New Once-Daily Viekira Pak Formulation Accepted by FDA
FDA decision expected in second half of 2016.
Amgen Submits Application to FDA for Humira Biosimilar
Submission bolstered by trials evaluating biosimilar candidate in moderate-to-severe plaque psoriasis and rheumatoid arthritis.
The Importance of Specialty Pharmacy Accreditation
Heather Bonome, PharmD, director of Pharmacy Segment at URAC, discusses why specialty pharmacies should seek accreditation.
Top Rheumatoid Arthritis Drug Underutilized
Research finds patients are not staying on methotrexate long enough before switching to more costly biologic drugs.
Ten Most Read Articles on Specialty Pharmacy Times in November
Catch up with any news you missed last month.
FDA Approves New Multiple Myeloma Combination Therapy
Empliciti combination decreased disease progression risk by 30%.
Early Study Evaluating Multiple Myeloma Drug
Reolysin plus bortezomib and dexamethasone treats patients with relapsed or refractory multiple myeloma.
Trends Developing in Specialty Pharmacy
David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, discusses developments affecting the specialty landscape.
ICYMI: Catch Up With the Most Recent Issue of Specialty Pharmacy Times
Top articles from the leading specialty pharmacy journal.
Experimental Immunotherapy Extends Bladder Cancer Survival
Experimental personalized peptide cancer vaccine found to extend overall survival.
Immunotherapy May Promote Rapid HPV Clearance
Therapeutic vaccine may reduce cervical cancer by fighting disease after infection.
Busy Week in Drug Approvals Highlight Specialty Pharmacy Week in Review
Top stories of the week on Specialty Pharmacy Times.
FDA Approves Non-Small Cell Lung Cancer Drug
Portrazza plus chemotherapy treats metastatic squamous non-small cell lung cancer in patients who were not previously treated specifically for advanced lung cancer.
Opdivo Approved for Renal Cell Carcinoma, Melanoma
Opdivo found to improve overall survival compared with other leading cancer therapies.
FDA Approves New Melanoma Combination Therapy
Tafinlar plus Mekinist found to improve overall survival in unresectable or metastatic BRAF-mutated melanoma.
How to Optimize Management of Specialty Therapies
Jon Hamrick, executive vice president, Biotech and Specialty Services at Therigy LLC, discusses techniques specialty pharmacies can use to improve workflow and clinical activities in therapy management.
Pharmacist Calls for Medical Marijuana to Meet Same Standards as Other Drugs
Concerns raised from combining medical marijuana dispensaries with recreational dispensaries.
FDA Approves New Treatment for Refractory Multiple Myeloma
Ixazomib is an oral proteasome inhibitor used in combination with lenalidomide and dexamethasone.
Half of Hepatitis C Patients on Medicaid Denied Drug Access
Patients on Medicaid more likely to have HCV infection and much more likely to be denied coverage.
Drug Spending and Access Limitations Highlight Specialty Pharmacy Week in Review
Global Drug Spending Projected to Reach $1.4 Trillion by 2020
Specialty drugs for chronic, rare, and genetic diseases are forecast to drive a $298 billion increase in brand spending.
FDA Accepts New Biosimilar Application from Sandoz
Treatment helps reduce infection risk from low white blood cell count in cancer patients receiving chemotherapy.
Blood Cancer Drug Successful in First Clinical Trial
Novel drug shows promise in chronic lymphocytic leukemia and non-Hodgkin lymphoma refractory or resistant to current chemotherapies.
Diplomat's Specialty Retail Network
Atheer Kaddis, PharmD, senior vice president of Business Development and Sales at Diplomat, discusses retail network services.
FDA Delays Decision on New Lung Cancer Drug
FDA requests a more thorough review of rociletinib from ongoing trial.
Opdivo Granted Priority Review for Advanced Renal Cell Carcinoma
Opdivo shows extended overall survival and fewer adverse events in patients with RCC compared with Afinitor.